These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 16926630)

  • 1. Synergistic cytotoxic interaction in hormone-refractory prostate cancer with the triple combination docetaxel-erlotinib and 5-fluoro-5'-deoxyuridine.
    Fischel JL; Ciccolini J; Formento P; Ferrero JM; Milano G
    Anticancer Drugs; 2006 Aug; 17(7):807-13. PubMed ID: 16926630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Taxotere-5'-deoxy-5-fluorouridine combination on hormone-refractory human prostate cancer cells.
    Fischel JL; Ferrero JM; Formento P; Ciccolini J; Renée N; Formento JL; Milano G
    Anticancer Drugs; 2005 Mar; 16(3):309-16. PubMed ID: 15711183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid.
    Ullén A; Lennartsson L; Harmenberg U; Hjelm-Eriksson M; Kälkner KM; Lennernäs B; Nilsson S
    Acta Oncol; 2005; 44(6):644-50. PubMed ID: 16165924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer.
    Fizazi K; Sikes CR; Kim J; Yang J; Martinez LA; Olive MC; Logothetis CJ; Navone NM
    Anticancer Res; 2004; 24(5A):2897-903. PubMed ID: 15517894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo.
    Henry JY; Lu L; Adams M; Meyer B; Bartlett JB; Dalgleish AG; Galustian C
    Prostate; 2012 Jun; 72(8):856-67. PubMed ID: 21968939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ciprofloxacin sensitizes hormone-refractory prostate cancer cell lines to doxorubicin and docetaxel treatment on a schedule-dependent manner.
    Pinto AC; Moreira JN; Simões S
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):445-54. PubMed ID: 19104815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase inhibitor potentiates anticancer effect of docetaxel via modulation of Bcl-2 family proteins and tubulin in hormone refractory prostate cancer cells.
    Hwang JJ; Kim YS; Kim MJ; Kim DE; Jeong IG; Kim CS
    J Urol; 2010 Dec; 184(6):2557-64. PubMed ID: 21030039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel (Taxotere) in hormone-refractory prostate cancer.
    Petrylak DP
    Semin Oncol; 2000 Apr; 27(2 Suppl 3):24-9. PubMed ID: 10810935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of growth factors in hormone- and drug-resistant prostate cancer cells by synergistic combination of docetaxel and octreotide.
    Erten C; Karaca B; Kucukzeybek Y; Gorumlu G; Cengiz E; Gul MK; Atmaca H; Uzunoglu S; Karabulut B; Sanli UA; Uslu R
    BJU Int; 2009 Jul; 104(1):107-14. PubMed ID: 19191785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants.
    Chefrour M; Milano G; Formento P; Giacometti S; Denden A; Renée N; Iliadis A; Fischel JL; Ciccolini J
    Fundam Clin Pharmacol; 2012 Aug; 26(4):530-7. PubMed ID: 21623901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.
    Domingo-Domenech J; Oliva C; Rovira A; Codony-Servat J; Bosch M; Filella X; Montagut C; Tapia M; Campás C; Dang L; Rolfe M; Ross JS; Gascon P; Albanell J; Mellado B
    Clin Cancer Res; 2006 Sep; 12(18):5578-86. PubMed ID: 17000695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines.
    Kübler HR; van Randenborgh H; Treiber U; Wutzler S; Battistel C; Lehmer A; Wagenpfeil S; Hartung R; Paul R
    Prostate; 2005 Jun; 63(4):385-94. PubMed ID: 15617027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results.
    Picus J; Schultz M
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):14-8. PubMed ID: 10604263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells.
    Pu YS; Hsieh MW; Wang CW; Liu GY; Huang CY; Lin CC; Guan JY; Lin SR; Hour TC
    Biochem Pharmacol; 2006 Mar; 71(6):751-60. PubMed ID: 16413505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
    Sirotnak FM; Zakowski MF; Miller VA; Scher HI; Kris MG
    Clin Cancer Res; 2000 Dec; 6(12):4885-92. PubMed ID: 11156248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine.
    Magné N; Fischel JL; Dubreuil A; Formento P; Ciccolini J; Formento JL; Tiffon C; Renée N; Marchetti S; Etienne MC; Milano G
    Clin Cancer Res; 2003 Oct; 9(13):4735-42. PubMed ID: 14581344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined effect of sodium selenite and docetaxel on PC3 metastatic prostate cancer cell line.
    Freitas M; Alves V; Sarmento-Ribeiro AB; Mota-Pinto A
    Biochem Biophys Res Commun; 2011 May; 408(4):713-9. PubMed ID: 21549092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of oral fluoropyrimidine and docetaxel: reappraisal of synergistic effect against gastric carcinoma xenografts.
    Kodera Y; Fujiwara M; Yokoyama H; Ohashi N; Miura S; Ito Y; Koike M; Ito K; Nakao A
    In Vivo; 2005; 19(5):861-6. PubMed ID: 16097439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormone refractory prostate cancer: Management and advances.
    Sonpavde G; Hutson TE; Berry WR
    Cancer Treat Rev; 2006 Apr; 32(2):90-100. PubMed ID: 16458434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.